Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status

Table 1

Therapeutic application of OML-based vaccine in murine, bovine, and human models.

Encased materials	Responses	Animal or source	Route	References
OVA	Elimination of established E.G7-OVA tumor	C57/BL6	s.c.	[24, 53]
Crude extract of Leishmania	Suppression of footpad swelling by Leishmania major infection	Balb/c	i.p.	[22]
Recombinant NcGRA7	Protection of dams and offspring from Neospora caninum infection	Balb/c	s.c.	[23]
Recombinant apical membrane antigen 1	Reduction of offspring mortality from Neospora caninum infection	Balb/c	s.c.	[62]
Cry j 1	Prevention of IgE elevation in sera in response to Cry j 1 sensitization	Balb/c	s.c.	[25]
OVA	Induce mucosal immune responses and suppression of development of allergic diarrhea induced by oral OVA administration	Balb/c	i.n.	[67, 68]
αGalCer	More effective expansion of NKT cells	C57/BL6	i.p.	[60]
Recombinant NcGRA7	Suppression of serum IFN-γ elevation by infection of Neospora, suppression of Neospora infection in brain	Cattle	s.c.	[63]
HLA-restricted HTLV-1 Tax epitope peptide	Induction of HTLV-1-specific CTL	HLA-transgenic mouse	s.c.	[70]
	Induction of HTLV-1-specific CTL	PBMC from HTLV-1 carriers	In vitro
HLA-A24-restricted surviving 2B epitope peptide	Induction of CTL specific for HLA-restricted surviving 2B epitope	PBMC from patients	In vitro	^a
	Elimination of established surviving 2B-positive tumor	HLA-transgenic mouse	s.c.
Human papillomavirus DNA	Induction of papillomavirus-specific CTL	PBMC from carriers	In vitro	[71]

i.n.: intranasal.
^aPersonal communication.